Skip to main content
. 2019 Feb 4;8(3):1269–1278. doi: 10.1002/cam4.2006

Figure 4.

Figure 4

Expression of HER2 and survival, proliferation, phenotypes of epithelial‐to‐mesenchymal transition (EMT), stemness and invasiveness of HER2‐positive hepatoma cells. A. Effect of HER2 inhibition on the survival of HepG2, JM1 and HER2‐transfected McA cells. B. HER2 inhibition can decrease proliferation of HepG2, JM1 and HER2‐transfected McA cells. Trastuzumab with the concentrations of 30 and 100 μg/ml suppressed cell proliferation after 48 hours of EGF stimulation (*versus data of control, P < 0.05). C. The decreased level of E‐cadherin and the increased level of Vimentin indicates EMT in JM1 with TGF‐β (0.5μg/ml) for 40 days. HER2 expression follows pattern of Vimentin or mesenchymal character of transit. D. Expression of HER2, β‐catenin, CD133 and MMP‐9 in both the transformed JM1 cells (JM/6+) and naïve JM1 cells, and effect of HER2 inhibition on deceased level of β‐catenin, CD133 and MMP‐9.